Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, has announced that it has partnered with The Macular Society to continue to support the advancement of new treatment options in eyecare across the UK.
The Macular Society aims to raise awareness of eye health, providing services to patients across the UK suffering from the debilitating condition of age-related macular degeneration (AMD). Ora has been working to increase awareness amongst the patient community about the scope of ophthalmic clinical trials, with the aim of improving understanding of clinical research as a care option and enhancing the patient experience during the study process.
“Macular disease is the biggest cause of sight loss in the UK and has a devastating impact on so many people's lives,” said Geraldine Hoad, research manager for the Macular Society. “Patients play a vital role in research. Without them, new treatments would not be developed and the progress we have seen to date would not be possible. By working with Ora we hope we can encourage more patients to take part in these trials and understand the wide-ranging benefits of being involved in research.”
The partnership is a critical step in supporting the continued advancement of treatment options for eyecare, educating the patient population and increasing awareness of clinical research within local communities throughout the UK.
“People with chronic conditions such as dry AMD don’t have any current avenues for treatment, and without clinical research, they may be left without any ability to manage their conditions on a day-to-day basis,” commented Sally Tucker, Vice President Ora Europe, MCOptom, PhD. We know there is a lack of awareness and education surrounding clinical research and together with the Macular Society, we aim to change this so that we can better understand the impact of diseases alongside how sponsors, researchers and ophthalmic professionals can pave a better path for clinical research in eyecare across the UK.”